Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.11
-1.19 (-7.78%)
At close: Mar 3, 2026, 4:00 PM EST
14.07
-0.04 (-0.28%)
Pre-market: Mar 4, 2026, 5:36 AM EST
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Amylyx Pharmaceuticals stock have an average target of 18.89, with a low estimate of 8.00 and a high estimate of 28. The average target predicts an increase of 33.88% from the current stock price of 14.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +48.83% | Mar 3, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $15 → $19 | Strong Buy | Maintains | $15 → $19 | +34.66% | Feb 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +98.44% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $20 | Strong Buy | Maintains | $16 → $20 | +41.74% | Nov 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $12 → $20 | Strong Buy | Maintains | $12 → $20 | +41.74% | Oct 17, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.57M
EPS This Year
-1.39
from -1.53
EPS Next Year
-1.42
from -1.39
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 132.0M | |||
| Avg | n/a | 45.6M | |||
| Low | n/a | 4.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.84 | -0.95 | |||
| Avg | -1.39 | -1.42 | |||
| Low | -1.61 | -1.56 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.